Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 18Prostatic Neoplasms 8Osteoporosis 8Vitamin D Deficiency 4Polycystic Ovary Syndrome 4Colonic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Colorectal Neoplasms 3Bone Diseases, Metabolic 3Obesity 2Neoplasm Metastasis 2Multiple Endocrine Neoplasia Type 1 2Lymphoma 2Lung Neoplasms 2Leukemia 2Inflammation 2Cardiovascular Diseases 2Carcinoma, Transitional Cell 2Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Solid Cancers 1Sexual Dysfunction, Physiological 1Rectal Neoplasms 1Psoriasis 1Pancreatic Neoplasms 1

Interventions

Denosumab 5Vitamin D 1Dasatinib 1Curettage 1Calcium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Giant Cell Tumor of Bone × Vitamin D × Clear all
NCT00396279 2022-11-08

Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone

Amgen

Phase 2 Completed
37 enrolled 13 charts

Giant Cell Tumor of Bone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡